Full-Time

Laboratory Assistant

Posted on 4/8/2025

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Entry, Junior

Company Does Not Provide H1B Sponsorship

Lenexa, KS, USA

Category
Lab & Research
Life Sciences
Requirements
  • High school diploma or equivalent; associate degree in a relevant field preferred.
  • 0-2 years of experience in a laboratory or related environment, with a strong willingness to learn and develop new skills.
  • Strong attention to detail and organizational skills, with the ability to handle multiple tasks efficiently.
  • Good communication and teamwork abilities, with a proactive approach to supporting laboratory operations.
  • Basic familiarity with laboratory equipment and techniques is a plus.
Responsibilities
  • Assisting with the preparation of laboratory samples and reagents according to established protocols and procedures.
  • Maintaining laboratory equipment and supplies, ensuring cleanliness and proper functioning at all times.
  • Documenting and tracking sample information, including labeling, storage, and retrieval of samples as needed.
  • Supporting laboratory staff in conducting tests and analyses by providing timely assistance and preparation of materials.
  • Participating in maintaining a safe and compliant laboratory environment, following all safety protocols and guidelines.
Desired Qualifications
  • Basic familiarity with laboratory equipment and techniques is a plus.

Icon provides consulting, development, and commercialization services to help clients accelerate the creation of drugs and medical devices. Their services are designed to improve the quality of life by ensuring that these products reach the market efficiently. Icon operates a global network of offices in 53 countries, allowing them to offer localized support while maintaining high standards of quality. They focus on key factors such as reducing time to market, lowering costs, and enhancing quality, setting them apart from competitors. The goal of Icon is to support clients in bringing life-saving and life-enhancing products to market more effectively.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances clinical trial efficiency and participant satisfaction.
  • Appointment of Barry Balfe as COO expected to drive growth and enhance customer value.
  • Recognition as Europe's Climate Leader enhances brand reputation and attracts eco-conscious clients.

What critics are saying

  • Securities fraud lawsuit could damage ICON's reputation and affect future business opportunities.
  • Integration challenges with Mural Health partnership may lead to delays or increased costs.
  • Underutilization of biomarkers in trials could hinder competitive advantage in neurodegenerative research.

What makes Icon unique

  • ICON offers a full range of consulting, development, and commercialization services globally.
  • The company focuses on reducing time to market, cost, and increasing quality for clients.
  • ICON has extensive experience in a broad range of therapeutic areas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

PharmiWeb
Mar 4th, 2025
​​Mural Health And Icon Announce Partnership To Enhance Participant And Site Experience In Clinical Trials​

BERWYN, PENNSYLVANIA and DUBLIN, IRELAND, 4 March 2025 - Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link. ICON will ​utilise​ Mural Link’s innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. “From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation,” said Sam Whitaker, CEO of Mural Health. “This partnership represents a shared vision of removing barriers to trial participation​ and advancing participation financial neutrality​, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities.”

PharmiWeb
Jan 9th, 2025
Biomarker And Trial Optimisation Needed To Drive R&D Progress In Alzheimer’S And Related Disorders – Icon Survey

Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s RD’. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation

INACTIVE